An Edinburgh-based marine biotech business has been given a £50,000
(€73 000) boost in its bid to scour tidal areas such as rock pools
to find and develop new drugs and antibiotics, including a new
compound found to be active against...
Drug development and biomedical company Thuris and Italian
pharmaceutical company Sigma-Tau Industrie Farmaceutiche Riunite on
Monday announced an expansion of their ongoing research
collaboration to develop compounds to combat brain...
Swiss life-science company Lonza announced on Tuesday that it is to
strengthen the production of oligonucleotides - an emerging new
class of therapeutics consisting of short nucleic acid chains
interfering in the processing of genetic...
Women are becoming the most attractive target audience for
healthcare companies, claims a new report from market analysts
Datamonitor. A combination of increasing Internet access, a general
interest in health issues among women along...
In the second news of the day on a European life science company,
DSM announced this week that from now on it will supply
technologies and services for the initial development phases of new
medicines - supplementing its existing service...
The US Food and Drug Administration announced this week that it has
accomplished the initial objectives outlined in its ongoing
initiative to modernise the agency's regulation of pharmaceutical
manufacturing and product quality.
UK Shire Pharmaceuticals group said this week that its US
subsidiary Shire Laboratories has filed a lawsuit in the US
District Court against Barr Laboratories for the infringement of
the US patent No. 6,322,819 ( '819 Patent')
Japanese company Kaken Pharmaceutical and US Elitra Pharmaceuticals
said yesterday that they are to collaborate on a multi-year
research project for the discovery and development of novel
AstraZeneca Canada has received approval from the Therapeutic
Products Directorate of Health Canada to market CRESTOR
(rosuvastatin) 10 to 40 mg, a new medicine for the management of
primary high cholesterol (primary hypercholesterolemia),...
Nabi Biopharmaceuticals saw biopharmaceutical product sales -
driven by strong growth in sales of Nabi-HB - reaching record
levels of $89.5 million (€83m) in 2002, a 22 per cent increase from
US demand for combinatorial chemistry products and services is set
to increase by more than twelve per cent annually to reach $4
billion (€3.7bn) in 2006, according to a new report from market
analyst the Freedonia group.
Danish company Novozymes announced yesterday that the US Department
of Energy (DOE) has approved the third year of funding for
Novozymes' three-year subcontract to develop more cost-efficient
enzymes for ethanol production.